CRISPR-Cas9 Gene Editing for Sickle Cell Disease and beta-Thalassemia.
Frangoul H, Altshuler D, Cappellini MD, Chen YS, Domm J, Eustace BK, Foell J, de la Fuente J, Grupp S, Handgretinger R, Ho TW, Kattamis A, Kernytsky A, Lekstrom-Himes J, Li AM, Locatelli F, Mapara MY, de Montalembert M, Rondelli D, Sharma A, Sheth S, Soni S, Steinberg MH, Wall D, Yen A, Corbacioglu S.
N Engl J Med. 2021 Jan 21;384(3):252-260. doi: 10.1056/NEJMoa2031054. Epub 2020 Dec 5.
CRISPR/Cas9 gene editing for curing sickle cell disease.
Park SH, Bao G.
Transfus Apher Sci. 2021 Feb;60(1):103060. doi: 10.1016/j.transci.2021.103060. Epub 2021 Jan 10.
In vivo HSC prime editing rescues sickle cell disease in a mouse model.
Li C, Georgakopoulou A, Newby GA, Chen PJ, Everette KA, Paschoudi K, Vlachaki E, Gil S, Anderson AK, Koob T, Huang L, Wang H, Kiem HP, Liu DR, Yannaki E, Lieber A.
Blood. 2023 Apr 27;141(17):2085-2099. doi: 10.1182/blood.2022018252.
The Next Frontier in Noninvasive Prenatal Diagnostics: Cell-Free Fetal DNA Analysis for Monogenic Disease Assessment.
Zhong LPW, Chiu RWK.
Annu Rev Genomics Hum Genet. 2022 Aug 31;23:413-425. doi: 10.1146/annurev-genom-110821-113411. Epub 2022 Mar 22.
CRISPR/Cas9 for Sickle Cell Disease: Applications, Future Possibilities, and Challenges.
Demirci S, Leonard A, Haro-Mora JJ, Uchida N, Tisdale JF.
Adv Exp Med Biol. 2019;1144:37-52. doi: 10.1007/5584_2018_331.
Alpha-thalassaemia.
Harteveld CL, Higgs DR.
Orphanet J Rare Dis. 2010 May 28;5:13. doi: 10.1186/1750-1172-5-13.
Monogenic disease analysis establishes that fetal insulin accounts for half of human fetal growth.
Hughes AE, De Franco E, Freathy RM; Fetal Insulin and Growth Consortium; Flanagan SE, Hattersley AT.
J Clin Invest. 2023 Mar 15;133(6):e165402. doi: 10.1172/JCI165402.
Non-invasive prenatal sequencing for multiple Mendelian monogenic disorders using circulating cell-free fetal DNA.
Zhang J, Li J, Saucier JB, Feng Y, Jiang Y, Sinson J, McCombs AK, Schmitt ES, Peacock S, Chen S, Dai H, Ge X, Wang G, Shaw CA, Mei H, Breman A, Xia F, Yang Y, Purgason A, Pourpak A, Chen Z, Wang X, Wang Y, Kulkarni S, Choy KW, Wapner RJ, Van den Veyver IB, Beaudet A, Parmar S, Wong LJ, Eng CM.
Nat Med. 2019 Mar;25(3):439-447. doi: 10.1038/s41591-018-0334-x. Epub 2019 Jan 28.
Genome editing approaches to β-hemoglobinopathies.
Brusson M, Miccio A.
Prog Mol Biol Transl Sci. 2021;182:153-183. doi: 10.1016/bs.pmbts.2021.01.025. Epub 2021 Mar 1.
Engineered human hepatocyte organoids enable CRISPR-based target discovery and drug screening for steatosis.
Hendriks D, Brouwers JF, Hamer K, Geurts MH, Luciana L, Massalini S, López-Iglesias C, Peters PJ, Rodríguez-Colman MJ, Chuva de Sousa Lopes S, Artegiani B, Clevers H.
Nat Biotechnol. 2023 Nov;41(11):1567-1581. doi: 10.1038/s41587-023-01680-4. Epub 2023 Feb 23.
